Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Continuity-Bioscience

More Like This

PR Newswire associated0

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

PR Newswire associated0

A Global Milestone in Innovative Pancreatic Cancer Therapy

PR Newswire associated0

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

PR Newswire associated0

Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery

PR Newswire associated0

Calyx Medical Imaging Supports Groundbreaking Melanoma Treatment Approval

PR Newswire associated0

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

PR Newswire associated0

Seeking Investors: First-in-Class Immunotherapeutics for Cancer